Immunogenicity and safety of intradermal influenza vaccine in children

Susanna Esposito, Cristina Daleno, Irene Picciolli, Laura Tagliaferri, Alessia Scala, Giulia Prunotto, Valentina Montinaro, Carlotta Galeone, Nicola Principi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

In order to compare the immunogenicity and safety of different doses of trivalent influenza vaccine (TIV) administered intradermallly (ID) with those evoked by a full dose of intramuscular (IM) virosomal-adjuvanted influenza vaccine (VA-TIV), 112 previously primed healthy children aged ≥3 years were randomised to receive 9 μg or 15 μg of each strain of ID-TIV, or a full IM dose (15 μg of each strain) of VA-TIV. The A/H1N1 and A/H3N2 seroconversion and seroprotection rates were ≥90% and geometric mean titres (GMTs) increased 3.2-14.9 times without any statistically significant between-group differences; however, the seroconversion and seroprotection rates against the B strain were significantly higher in the children receiving either ID-TIV dose (p<0.05) without any differences between them. GMT against B virus was significantly higher in the children receiving the highest dose (p<0.05). Local reactions were significantly more common among the children receiving either ID-TIV dose (p<0.05), but systemic reactions were relatively uncommon in all three groups. Our findings suggest that ID-TIV with 15 μg of each viral antigen can confer a significant better protection against influenza than that obtained with the same dose of IM TIV in already primed children aged ≥3 years with an acceptable safety profile. The lower dose of ID-TIV needs further evaluation to analyze persistence of protection.

Original languageEnglish
Pages (from-to)7606-7610
Number of pages5
JournalVaccine
Volume29
Issue number44
DOIs
Publication statusPublished - Oct 13 2011

Fingerprint

Influenza Vaccines
influenza
immune response
vaccines
Safety
dosage
seroconversion
Cercopithecine Herpesvirus 1
Macacine herpesvirus 1
Viral Antigens
viral antigens
Human Influenza

Keywords

  • Children
  • Influenza
  • Influenza vaccination
  • Intradermal influenza vaccine
  • Pediatrics

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Esposito, S., Daleno, C., Picciolli, I., Tagliaferri, L., Scala, A., Prunotto, G., ... Principi, N. (2011). Immunogenicity and safety of intradermal influenza vaccine in children. Vaccine, 29(44), 7606-7610. https://doi.org/10.1016/j.vaccine.2011.08.021

Immunogenicity and safety of intradermal influenza vaccine in children. / Esposito, Susanna; Daleno, Cristina; Picciolli, Irene; Tagliaferri, Laura; Scala, Alessia; Prunotto, Giulia; Montinaro, Valentina; Galeone, Carlotta; Principi, Nicola.

In: Vaccine, Vol. 29, No. 44, 13.10.2011, p. 7606-7610.

Research output: Contribution to journalArticle

Esposito, S, Daleno, C, Picciolli, I, Tagliaferri, L, Scala, A, Prunotto, G, Montinaro, V, Galeone, C & Principi, N 2011, 'Immunogenicity and safety of intradermal influenza vaccine in children', Vaccine, vol. 29, no. 44, pp. 7606-7610. https://doi.org/10.1016/j.vaccine.2011.08.021
Esposito S, Daleno C, Picciolli I, Tagliaferri L, Scala A, Prunotto G et al. Immunogenicity and safety of intradermal influenza vaccine in children. Vaccine. 2011 Oct 13;29(44):7606-7610. https://doi.org/10.1016/j.vaccine.2011.08.021
Esposito, Susanna ; Daleno, Cristina ; Picciolli, Irene ; Tagliaferri, Laura ; Scala, Alessia ; Prunotto, Giulia ; Montinaro, Valentina ; Galeone, Carlotta ; Principi, Nicola. / Immunogenicity and safety of intradermal influenza vaccine in children. In: Vaccine. 2011 ; Vol. 29, No. 44. pp. 7606-7610.
@article{362952c9c80246418306c61e57740683,
title = "Immunogenicity and safety of intradermal influenza vaccine in children",
abstract = "In order to compare the immunogenicity and safety of different doses of trivalent influenza vaccine (TIV) administered intradermallly (ID) with those evoked by a full dose of intramuscular (IM) virosomal-adjuvanted influenza vaccine (VA-TIV), 112 previously primed healthy children aged ≥3 years were randomised to receive 9 μg or 15 μg of each strain of ID-TIV, or a full IM dose (15 μg of each strain) of VA-TIV. The A/H1N1 and A/H3N2 seroconversion and seroprotection rates were ≥90{\%} and geometric mean titres (GMTs) increased 3.2-14.9 times without any statistically significant between-group differences; however, the seroconversion and seroprotection rates against the B strain were significantly higher in the children receiving either ID-TIV dose (p<0.05) without any differences between them. GMT against B virus was significantly higher in the children receiving the highest dose (p<0.05). Local reactions were significantly more common among the children receiving either ID-TIV dose (p<0.05), but systemic reactions were relatively uncommon in all three groups. Our findings suggest that ID-TIV with 15 μg of each viral antigen can confer a significant better protection against influenza than that obtained with the same dose of IM TIV in already primed children aged ≥3 years with an acceptable safety profile. The lower dose of ID-TIV needs further evaluation to analyze persistence of protection.",
keywords = "Children, Influenza, Influenza vaccination, Intradermal influenza vaccine, Pediatrics",
author = "Susanna Esposito and Cristina Daleno and Irene Picciolli and Laura Tagliaferri and Alessia Scala and Giulia Prunotto and Valentina Montinaro and Carlotta Galeone and Nicola Principi",
year = "2011",
month = "10",
day = "13",
doi = "10.1016/j.vaccine.2011.08.021",
language = "English",
volume = "29",
pages = "7606--7610",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "44",

}

TY - JOUR

T1 - Immunogenicity and safety of intradermal influenza vaccine in children

AU - Esposito, Susanna

AU - Daleno, Cristina

AU - Picciolli, Irene

AU - Tagliaferri, Laura

AU - Scala, Alessia

AU - Prunotto, Giulia

AU - Montinaro, Valentina

AU - Galeone, Carlotta

AU - Principi, Nicola

PY - 2011/10/13

Y1 - 2011/10/13

N2 - In order to compare the immunogenicity and safety of different doses of trivalent influenza vaccine (TIV) administered intradermallly (ID) with those evoked by a full dose of intramuscular (IM) virosomal-adjuvanted influenza vaccine (VA-TIV), 112 previously primed healthy children aged ≥3 years were randomised to receive 9 μg or 15 μg of each strain of ID-TIV, or a full IM dose (15 μg of each strain) of VA-TIV. The A/H1N1 and A/H3N2 seroconversion and seroprotection rates were ≥90% and geometric mean titres (GMTs) increased 3.2-14.9 times without any statistically significant between-group differences; however, the seroconversion and seroprotection rates against the B strain were significantly higher in the children receiving either ID-TIV dose (p<0.05) without any differences between them. GMT against B virus was significantly higher in the children receiving the highest dose (p<0.05). Local reactions were significantly more common among the children receiving either ID-TIV dose (p<0.05), but systemic reactions were relatively uncommon in all three groups. Our findings suggest that ID-TIV with 15 μg of each viral antigen can confer a significant better protection against influenza than that obtained with the same dose of IM TIV in already primed children aged ≥3 years with an acceptable safety profile. The lower dose of ID-TIV needs further evaluation to analyze persistence of protection.

AB - In order to compare the immunogenicity and safety of different doses of trivalent influenza vaccine (TIV) administered intradermallly (ID) with those evoked by a full dose of intramuscular (IM) virosomal-adjuvanted influenza vaccine (VA-TIV), 112 previously primed healthy children aged ≥3 years were randomised to receive 9 μg or 15 μg of each strain of ID-TIV, or a full IM dose (15 μg of each strain) of VA-TIV. The A/H1N1 and A/H3N2 seroconversion and seroprotection rates were ≥90% and geometric mean titres (GMTs) increased 3.2-14.9 times without any statistically significant between-group differences; however, the seroconversion and seroprotection rates against the B strain were significantly higher in the children receiving either ID-TIV dose (p<0.05) without any differences between them. GMT against B virus was significantly higher in the children receiving the highest dose (p<0.05). Local reactions were significantly more common among the children receiving either ID-TIV dose (p<0.05), but systemic reactions were relatively uncommon in all three groups. Our findings suggest that ID-TIV with 15 μg of each viral antigen can confer a significant better protection against influenza than that obtained with the same dose of IM TIV in already primed children aged ≥3 years with an acceptable safety profile. The lower dose of ID-TIV needs further evaluation to analyze persistence of protection.

KW - Children

KW - Influenza

KW - Influenza vaccination

KW - Intradermal influenza vaccine

KW - Pediatrics

UR - http://www.scopus.com/inward/record.url?scp=80053588703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053588703&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.08.021

DO - 10.1016/j.vaccine.2011.08.021

M3 - Article

VL - 29

SP - 7606

EP - 7610

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 44

ER -